Advanced search
Publication Cover
Cancer Investigation Volume 23, 2005 - Issue 1
Submit an article Journal homepage
12
Views
2
CrossRef citations to date
0
Altmetric
Brief Clinical Report

Prolonged Disease-Free and Treatment-Free Survival in Platinum-Resistant Ovarian Cancer Following Extended (> 1 Year) Administration of Single-Agent Paclitaxel: A Case Report and Discussion of Potential Clinical Implications

Maurie Markman Department of Medical Gynecologic Oncology, University of Texas M.D. Anderson Cancer Center, (Mail Box # 121), 1515 Holcombe Boulevard, Houston, Texas, 77030, USA; Department of Medical Gynecologic Oncology, University of Texas M.D. Anderson Cancer Center, (Mail Box # 121), 1515 Holcombe Boulevard, Houston, TX, 77030, USA
, M.D.,
Kenneth Webster Department of Gynecology/Obstetrics, The Cleveland Clinic Foundation, Cleveland, OhioUSA
,
Barbara Kulp Department of Gynecology/Obstetrics, The Cleveland Clinic Foundation, Cleveland, OhioUSA
&
Gertrude Peterson Department of Gynecology/Obstetrics, The Cleveland Clinic Foundation, Cleveland, OhioUSA
Pages 33-35 | Published online: 11 Jun 2009

References

  • The ICON and AGO Collaborators, Paclitaxel plus platinum-based chemotherapy vs. conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003, 361, 2099–2106.
  • Markman, M.; Bookman, M A. Second-line treatment of ovarian cancer. Oncologist 2000, 5, 26–35. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
  • Markman, M. Ovarian carcinoma: Management after first-line therapy. J. Pelvic Surg. 2000, 6, 27–33.
  • McGuire, W P.; Rowinsky, E K.; Rosenshein, N B.; Grumbine, F C.; Ettinger, D S.; Armstrong, D K.; Donehower, R C. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann. Intern. Med. 1989, 111, 273–279. [PUBMED], [INFOTRIEVE]
  • Thigpen, J T.; Blessing, J A.; Ball, H.; Hummel, S J.; Barrett, R J. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. J. Clin. Oncol. 1994, 12, 1748–1753. [PUBMED], [INFOTRIEVE]
  • Einzig, A I.; Wiernik, P H.; Sasloff, J.; Runowicz, C D.; Goldberg, G L. Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma. J. Clin. Oncol. 1992, 10, 1748–1753. [PUBMED], [INFOTRIEVE]
  • Kohn, E C.; Sarosy, G.; Bicher, A.; Link, C.; Christian, M.; Steinberg, S M.; Rothenberg, M.; Orvis Adamo, D.; Davis, P.; Ognibene, F P.; Cunnion, R E.; Reed, E. Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer. J. Natl. Cancer Inst. 1994, 86, 18–24. [PUBMED], [INFOTRIEVE]
  • Eisenhauer, E A.; ten Bokkel Huinink, W W.; Swenerton, K D.; Gianni, L.; Myles, J.; van der Burg, M E.L.; Kerr, I.; Vermorken, J B.; Buser, K.; Colombo, N.; Bacon, M.; Santabarbara, P.; Onetto, N.; Winograd, B.; Canetta, R. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose vs. low-dose and long vs. short infusion. J. Clin. Oncol. 1994, 12, 2654–2666. [PUBMED], [INFOTRIEVE]
  • Lopes, N M.; Adams, E G.; Pitts, T W.; Bhuyan, B K. Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines. Cancer Chemother. Pharmacol. 1993, 32, 235–242. [PUBMED], [INFOTRIEVE], [CROSSREF]
  • Rowinsky, E K.; Donehower, R C.; Jones, R J.; Tucker, R W. Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol. Cancer Res. 1988, 48, 4093–4100. [PUBMED], [INFOTRIEVE]
  • Smith, R E.; Brown, A M.; Mamounas, E P.; Anderson, S J.; Lembersky, B C.; Atkins, J H.; Shibata, H R.; Baez, L.; DeFusco, P A.; Davila, E.; Tipping, S J.; Bearden, J D.; Thirlwell, M P. Randomized trial of 3-hour vs. 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project protocol B-26. J. Clin. Oncol. 1999, 17, 3403–3411. [PUBMED], [INFOTRIEVE]
  • Vaughn, D J.; Broome, C M.; Hussain, M.; Gutheil, J C.; Markowitz, A B. Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J. Clin. Oncol. 2002, 20, 937–940. [PUBMED], [INFOTRIEVE], [CROSSREF]
  • Fennelly, D.; Aghajanian, C.; Shapiro, F.; O'Flaherty, C.; McKenzie, M.; O'Connor, C.; Tong, W.; Norton, L.; Spriggs, D. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J. Clin. Oncol. 1997, 15, 187–192. [PUBMED], [INFOTRIEVE]
  • Markman, M.; Hall, J.; Spitz, D.; Weiner, S.; Carson, L.; Van Le, L.; Baker, M. Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer. J. Clin. Oncol. 2002, 20, 2365–2369. [PUBMED], [INFOTRIEVE], [CROSSREF]
  • Markman, M.; Hakes, T.; Barakat, R.; Curtin, J.; Almadrones, L.; Hoskins, W. Follow-up of Memorial Sloan-Kettering Cancer Center patients treated on National Cancer Institute Treatment Referral Center protocol 9103: paclitaxel in refractory ovarian cancer. J. Clin. Oncol. 1996, 14, 796–799. [PUBMED], [INFOTRIEVE]
  • Rohl, J.; Kushner, D.; Markman, M. Chronic administration of single-agent paclitaxel in gynecologic malignancies. Gynecol. Oncol. 2001, 81, 201–205. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
  • Von Gruenigen, V E.; Karlen, J R.; Waggoner, S E. A case of chronic paclitaxel administration in ovarian cancer. Gynecol. Oncol. 2003, 89, 532–535. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
  • Browder, T.; Butterfield, C E.; Kraling, B M.; Shi, B.; Marshall, B.; O'Reilly, M S.; Folkman, J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 2000, 60, 1878–1886. [PUBMED], [INFOTRIEVE]
  • Markman, M.; Liu, P Y.; Wilczynski, S.; Monk, B.; Copeland, L J.; Alvarez, R D.; Jiang, C.; Alberts, D. Phase III randomized trial of 12 vs. 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J. Clin. Oncol. 2003, 21, 2460–2465. [PUBMED], [INFOTRIEVE], [CROSSREF]

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.